Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Skin Type Determination Using Image Artificial Intelligence

NCT07765303 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2025-04-28
Last updated
2026-08-14

Condition(s) studied

Skin AgeingSkin

Investigational drug(s) / intervention(s)

Skin imaging and skin characteristic assessment

Skin imaging and skin characteristic assessment: Participants undergo standardized clinical and dermoscopic skin imaging, skin pigmentation measurements, skin phototype assessments, photodamage assessments, and completion of questionnaires. Data are collected for the development and validation of artificial intelligence algorithms for classification of skin pigmentation, phototype, and photodamage.

Study summary

Skin color, how easily a person burns or tans in the sun (skin phototype), and the amount of chronic sun damage in the skin are important factors in skin health. These characteristics influence a person's risk of skin cancer, how skin diseases appear, how well treatments work, and how accurately doctors and artificial intelligence (AI) systems can diagnose skin conditions. However, current methods for classifying these characteristics are often imprecise and rely heavily on subjective assessments. As a result, both healthcare professionals and patients may incorrectly classify skin type, which can lead to inaccurate risk assessments and less personalized care.

This study aims to develop and validate AI algorithms that can accurately classify skin pigmentation, skin phototype, and accumulated sun damage using photographs of the skin. Unlike existing approaches, the study combines several different methods to create a more objective "ground truth" for training the AI. These methods include skin color measurements using spectrophotometry or colorimetry, assessments using the Monk Skin Tone Scale, questionnaires about sun sensitivity, and clinical evaluations by trained observers. By combining these data sources, the researchers hope to create a more reliable and scientifically robust classification system.

The study will recruit adults aged 18 years and older from several countries, including countries from all continents. Participants will complete a questionnaire about their skin, propensity to burn and sun exposure history. Researchers will then take standardized close-up and dermoscopic images of the skin on the arm and forearm, measure skin pigmentation using objective instruments when available, and assess skin phototype and sun damage. No invasive procedures will be performed, and no personally identifiable information will be collected.

The collected images and measurements will be used to train deep learning AI models. The researchers aim to develop algorithms that can classify skin pigmentation with at least 85% accuracy, skin phototype with at least 75% accuracy, and sun damage with at least 80% accuracy compared with the combined reference assessments. The algorithms will then be tested in independent datasets, including large dermatology image databases from Sweden, to evaluate how well they perform in different populations.

The study has several potential benefits. More accurate classification of skin characteristics could improve personalized skin cancer risk assessments and allow prevention advice to be tailored to individual needs. This may help identify people who would benefit from closer surveillance and stronger sun protection recommendations while avoiding unnecessary restrictions for people at lower risk. Improved classification could also enhance the diagnosis and management of inflammatory skin diseases and skin cancers, which can appear differently in people with different skin tones.

An additional goal is to address known biases in dermatology AI systems, which often perform less accurately in individuals with darker skin. By including participants with a wide range of skin tones and backgrounds, the researchers aim to contribute to the benchmarking of AI-driven medical devices wich hopefully can result in the development of fairer and more equitable AI tools.

The study involves minimal risk. Only photographs of the arm and forearm will be taken, and researchers will avoid capturing tattoos, prominent scars, or other identifying features. All data will be stored securely and only accessible to authorized researchers. The potential benefits of improving skin disease diagnosis, skin cancer prevention, and fairness in medical AI are considered to outweigh the small privacy risks associated with participation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 18 years or older * Able and willing to provide informed consent (oral or written, according to local regulations) * Willing to complete the study questionnaire * Willing to undergo non-invasive skin imaging and skin characteristic assessments of predefined sites on the upper arm and forearm Exclusion Criteria: * Younger than 18 years of age * Unable to provide informed consent * Unable to complete study procedures * Tattoos, prominent scars, wounds, skin lesions, dressings, or other identifiable features at the predefined imaging sites that may interfere with image acquisition, assessment quality, or participant anonymity

Primary outcome measure(s)

  • Agreement between AI-derived skin pigmentation (tone) classification and objective skin pigmentation measured by colorimetry/ spectrophotometry (Individual Typology Angle, ITA) — At completion of model development and testing (approximately 2029).
    Skin pigmentation will be measured objectively using spectrophotometry/ colorimetry and summarized as the Individual Typology Angle (ITA). AI-derived skin pigmentation classification will be compared with ITA values using correlation and agreement analyses. ITA is considered the primary reference standard for objective assessment of skin pigmentation in the interpretation of AI performance.
  • Accuracy of AI-based skin phototype classification — At completion of model development and testing (approximately 2029).
    Accuracy of the deep learning algorithm in classifying skin phototype from clinical and dermoscopic images compared with the reference standard based on the validated Fitzpatrick skin phototype assessment (consisting of 6 categories).
  • Agreement between AI-derived skin pigmentation (tone) classification and clinician-assessed Monk Skin Tone Scale category — At completion of model development and testing (approximately 2029).
    Skin pigmentation will be assessed visually by trained investigators using the Monk Skin Tone Scale (categories 1 (fair) to 10 (dark)). AI-derived classifications will be compared with clinician-assigned Monk categories using agreement and correlation analyses. The Monk Skin Tone Scale represents the principal visual reference standard for skin tone classification.
  • Agreement between AI-derived photodamage classification and the Clinical Photonumeric Scale for Photodamage Assessment — At completion of model development and testing (approximately 2029).
    Photodamage will be assessed using the validated Clinical Photonumeric Scale (0-3 for 3 defined pigmentation categories) for Photodamage Assessment. AI-derived photodamage classifications will be compared with the photonumeric scale scores using agreement and correlation analyses. This outcome evaluates the agreement between AI-derived classifications and a validated photonumeric clinical assessment of photodamage.

Trial sites (11)

FacilityCityRegionStatus
Hospital de Clínicas de Porto Alegre Porto Alegre Brazil Recruiting
Clinica Universidad de los Andes Santiago Chile Not Yet Recruiting
Hospital Clínico Universidad de Chile Santiago Chile Recruiting
Xiangya Hospital, Central South University Changsha China Not Yet Recruiting
Department of Dermatology, Odense University Hospital Odense Denmark Not Yet Recruiting
Queen Elisabeth Central Hospital Blantyre Malawi Not Yet Recruiting
Department of Dermatology, Hospital Universitario 12 de Octubre Madrid Spain Completed
University of Colombo Colombo Sri Lanka Enrolling By Invitation
Department of Dermatology Lund, Skåne University Hospital Lund Skåne County Recruiting
Department of Dermatology, Sahlgrenska University Hospital Gothenburg Västra Götaland County Recruiting
Siriraj Hospital, Mahidol University Bangkok Thailand Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07765303 on ClinicalTrials.gov ↗ ← All trials in Spain